ft 23 dec 92 lead articl drug price pharmaceut industri british govern current renegoti scheme control profit drug sale nation health servic govern negoti drive tough bargain argument favour exist agreement known pharmaceut price regul scheme long stand piec industri polici scheme prove singularli success control nh drug spend encourag british base pharmaceut sector high growth technolog industri uk among world leader pharmaceut one four world top 10 best sell patent medicin discov develop uk industri contribut trade surplu pound 1 3bn uk economi year scheme also advantag simplic practic fix return capit price individu drug administr bureaucraci kept minimum system wide admir countri one time french govern consid copi achiev tamper lightli real argument concern price set mechan price uk along rest world face inexor tendenc healthcar cost grow faster economi whole late 1980 rapid expans uk pharmaceut group earn rel inconspicu earli 1990 look like anomali glaxo made 38 per cent return capit worldwid last year smithklin beecham 45 per cent remark high return achiev research develop cost time sharpli rise budget deficit expenditur nh drug grow 12 per cent year although increas partli due govern inspir health programm expenditur growth scale jar time public expenditur constraint thu strong prima faci case adjust price control mechan appli nh perhap tighten return capit paramet current 17 20 per cent year industri argu lower return drive invest research oversea inde happen mid 1980 uk govern tri curb drug expenditur time though impact like limit world bleaker drug compani restrain price limit expenditur uk govern would follow exampl countri case uk retain power attract pool cheap invent scientist govern afford bargain hard